Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 1.01
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Data is available to registered users only
Buy
Sell